# AI Product Requirements Document (PRD)

**PRD Title**: ClinicalAssist AI - Diagnostic Decision Support System  
**Document ID**: PRD-2025-01-27-004  
**Version**: 1.0.0  
**Status**: In Review  
**Last Updated**: January 27, 2025  
**Author(s)**: Dr. Maria Thompson, VP Product - Clinical Systems  
**Reviewers**: Chief Medical Officer, CISO, Legal/Compliance, FDA Regulatory, Clinical Advisory Board

---

## Executive Summary

### Product Vision
An FDA-cleared AI assistant that augments physician decision-making by analyzing patient data, suggesting differential diagnoses, and recommending evidence-based treatment pathways while reducing diagnostic errors by 35%.

### The Opportunity
Diagnostic errors affect 12 million Americans annually, causing 40,000-80,000 deaths. Physicians spend only 13 minutes per patient while managing 20+ active cases. Our 1,200 physicians need tools to improve accuracy while maintaining efficiency.

### The Solution
A clinical decision support system that integrates with our EMR, analyzes patient history/symptoms/labs in real-time, provides ranked differential diagnoses with evidence, and suggests next steps - all while maintaining physician autonomy and documenting reasoning for compliance.

### Success Looks Like
- 35% reduction in diagnostic errors (measured via chart review)
- 25% reduction in unnecessary testing ($3.2M annual savings)
- 90% physician adoption within 12 months
- FDA 510(k) clearance obtained
- Zero safety events attributed to AI recommendations

---

## 1. Problem Definition

### 1.1 Core Problem Statement
> **Physicians make diagnostic errors in 10-15% of cases due to cognitive overload, time pressure, and incomplete information synthesis, resulting in 40,000+ preventable deaths annually in our network.**

### 1.2 Problem Evidence

#### Quantitative Evidence
| Metric | Current State | Source | Clinical Impact |
|--------|--------------|--------|-----------------|
| Diagnostic error rate | 10-15% | Chart audits | 40K-80K deaths/year |
| Time per patient | 13 minutes | EMR data | Rushed decisions |
| Missed critical values | 8% | Lab system | Delayed treatment |
| Cognitive burden | 20+ active cases | Physician survey | Decision fatigue |
| Test redundancy | 31% | Claims data | $4.8M waste/year |
| Readmission rate | 18% | Quality metrics | Poor outcomes |
| Malpractice claims | 34% diagnosis-related | Legal dept | $12M settlements/year |

#### Qualitative Evidence
- **Physician Quote**: "I'm constantly worried I'm missing something with only 13 minutes per patient" - Internal Medicine, Jan 2025
- **Patient Safety**: "Delayed lymphoma diagnosis by 6 months due to symptom complexity" - Incident report
- **Resident Quote**: "I need backup validation, especially during night shifts" - Survey feedback

#### Clinical Evidence Base
| Study | Finding | Relevance |
|-------|---------|-----------|
| JAMA 2024 | AI reduced diagnostic errors by 33% | Validates approach |
| NEJM 2024 | 87% physician satisfaction with AI support | Adoption feasible |
| BMJ 2023 | 41% reduction in unnecessary imaging | Cost savings |

### 1.3 Why Now?
- [x] Regulatory clarity: FDA guidance on clinical AI established
- [x] Technology maturity: Med-PaLM 2 achieves physician-level performance
- [x] EMR integration: FHIR standards enable real-time data access
- [x] Physician burnout: 63% report symptoms, need support tools
- [x] Value-based care: Quality metrics tied to reimbursement

### 1.4 Constraints & Requirements
- **Patient Safety**: Zero tolerance for life-threatening errors
- **Regulatory**: FDA 510(k) clearance required
- **Privacy**: HIPAA compliance mandatory
- **Clinical Validation**: 10,000+ case prospective study needed
- **Physician Autonomy**: Must not replace clinical judgment

---

## 2. Solution Design

### 2.1 Solution Hypothesis
> **An AI system analyzing comprehensive patient data and medical literature will reduce diagnostic errors by 35% and unnecessary testing by 25% while maintaining physician autonomy and regulatory compliance.**

### 2.2 Why AI?
| AI Capability | Clinical Value | Current Method | Improvement |
|---------------|---------------|----------------|-------------|
| Pattern Recognition | Spots rare diseases | Memory/experience | Catches zebras |
| Data Synthesis | Integrates 100+ data points | Manual review | Complete picture |
| Literature Access | 30M papers analyzed | Sporadic research | Evidence-based |
| Consistency | Never tired/biased | Human variability | Reliable quality |
| Speed | Sub-second analysis | Minutes of thinking | More patient time |

### 2.3 Clinical Workflow Integration
```
Patient Encounter ‚Üí EMR Data Extraction ‚Üí AI Analysis ‚Üí Clinical Review
        ‚Üì                    ‚Üì                ‚Üì              ‚Üì
   Chief Complaint      [History]      [Risk Scoring]    [Physician]
   Vital Signs         [Labs/Imaging]  [Differentials]   [Accepts/Modifies]
   Physical Exam       [Medications]   [Next Steps]      [Documents]
                            ‚Üì                ‚Üì              ‚Üì
                       FHIR Interface   Reasoning Engine  Audit Trail
                                             ‚Üì
                                    Clinical Knowledge Base
                                    (UpToDate, PubMed, Guidelines)
```

### 2.4 AI Model Specification
| Component | Specification | Clinical Validation |
|-----------|--------------|-------------------|
| Diagnostic Engine | Med-PaLM 2 fine-tuned | 92% accuracy vs experts |
| Risk Stratification | XGBoost ensemble | AUROC 0.94 |
| Drug Interactions | Graph neural network | 99.9% sensitivity |
| Imaging Analysis | RAD-BERT | 89% concordance |
| Clinical NLP | BioClinicalBERT | 96% entity extraction |
| Reasoning Chain | Custom transformer | Explainable decisions |

---

## 3. Behavioral Contract

### 3.1 Core Clinical Principles
1. **First, Do No Harm**: Never recommend dangerous actions
2. **Physician Empowerment**: Augment, never replace judgment
3. **Transparency**: Always show reasoning and confidence
4. **Evidence-Based**: Every recommendation cites sources
5. **Fail Safe**: When uncertain, escalate to specialist

### 3.2 Clinical Communication Style
- **Tone**: Professional, consultative, never directive
- **Language**: Medical terminology with lay translations
- **Confidence Display**: Percentage + confidence interval
- **Uncertainty Handling**: Clear about limitations

### 3.3 Clinical Behavioral Examples

#### Example 1: Standard Diagnostic Support
**Clinical Context**:
```
Patient: 45F
Chief Complaint: Chest pain, shortness of breath
Vitals: BP 145/90, HR 110, RR 22, O2 94%
History: Diabetes, recent long flight
Labs: D-dimer elevated, troponin negative
```

**Good Response** ‚úÖ:
```
‚ö†Ô∏è TIME-SENSITIVE DIFFERENTIALS

Based on clinical presentation and elevated D-dimer:

1. PULMONARY EMBOLISM (42% probability) üî¥ HIGH PRIORITY
   - Supporting: Recent flight, tachycardia, hypoxia, D-dimer
   - Wells Score: 4.5 (moderate risk)
   - Recommended: CT Angiography STAT
   - Evidence: [NEJM 2023, ESC Guidelines 2024]

2. Acute Coronary Syndrome (18% probability)
   - Against: Negative troponin (but early presentation)
   - Consider: Serial troponins, ECG
   - Evidence: [ACC/AHA Guidelines 2023]

3. Anxiety/Panic (15% probability)
   - Consider after ruling out life-threatening causes
   - Evidence: [DSM-5 criteria]

IMMEDIATE ACTIONS SUGGESTED:
‚ñ° Order CTA chest (if not contraindicated)
‚ñ° Continuous monitoring
‚ñ° Consider heparin per protocol if high suspicion
‚ñ° Cardiology consult if ECG changes

Clinical Confidence: 87% (based on 1,247 similar cases)
This suggestion requires physician verification
```

**Bad Response** ‚ùå:
```
Patient has PE. Start heparin immediately.
```
*Why it's bad*: Too directive, no reasoning, assumes diagnosis

#### Example 2: Rare Disease Detection
**Clinical Context**:
```
Patient: 12M pediatric
Symptoms: Developmental delay, coarse facial features, hepatomegaly
Labs: Elevated GAGs in urine
```

**Good Response** ‚úÖ:
```
üî¨ RARE DISEASE CONSIDERATION

Pattern Recognition Alert: Findings consistent with 
MUCOPOLYSACCHARIDOSIS (MPS)

Probability: 73% (High confidence)

Type Differentiation:
- MPS I (Hurler): 45% - Most severe, early onset
- MPS II (Hunter): 28% - X-linked, check family history  
- MPS VI (Maroteaux-Lamy): 15% - No CNS involvement

DIAGNOSTIC CONFIRMATION NEEDED:
1. Enzyme assays (definitive):
   - Œ±-L-iduronidase (MPS I)
   - Iduronate-2-sulfatase (MPS II)
   
2. Genetic testing for specific mutations

3. Immediate referrals:
   - Genetics (available: Dr. Smith, Tues PM)
   - Metabolic specialist

TIME-CRITICAL: Early enzyme replacement improves outcomes
Evidence: [Pediatrics 2024, Orphanet Database]

Similar cases in system: 3 (all confirmed MPS)
```

#### Example 3: Medication Safety Alert
**Clinical Context**:
```
Physician enters order: Metformin 1000mg BID
Patient eGFR: 28 mL/min
```

**Reject Response** üö´:
```
‚õî MEDICATION SAFETY ALERT

CONTRAINDICATION DETECTED:
Metformin is contraindicated with eGFR <30 mL/min

Risk: Lactic acidosis (mortality rate 50%)
Patient eGFR: 28 mL/min (Stage 4 CKD)

SAFER ALTERNATIVES:
1. DPP-4 inhibitors (sitagliptin) - Renal dose adjustment
2. GLP-1 agonists (semaglutide) - No renal adjustment
3. Insulin therapy - Titrate carefully

FDA Black Box Warning applies
Override requires attending authorization + documentation

Evidence: [FDA Safety Communication 2024, KDIGO Guidelines]
```

#### Example 4: Defensive Documentation
**Clinical Context**:
```
Patient leaving AMA with concerning symptoms
```

**Good Response** ‚úÖ:
```
üìã AMA DOCUMENTATION ASSISTANCE

For medical-legal protection, ensure documentation includes:

CAPACITY ASSESSMENT:
‚ñ° Patient alert and oriented x4
‚ñ° Understands medical condition
‚ñ° Understands risks of leaving (including death)
‚ñ° No evidence of impairment

RISKS DISCUSSED (document specific risks):
‚ñ° Potential MI/stroke (based on presentation)
‚ñ° Death or permanent disability
‚ñ° Worsening requiring emergency return

ATTEMPTS TO CONVINCE:
‚ñ° Offered alternatives (observation, expedited testing)
‚ñ° Involved family/support (if permitted)
‚ñ° Offered partial treatment

FOLLOW-UP:
‚ñ° Return precautions given (written)
‚ñ° Follow-up appointment scheduled
‚ñ° PCP notified

Suggested documentation template inserted in EMR
Malpractice risk mitigation: 73% reduction with proper documentation
```

#### Example 5: Pediatric Dosing
**Clinical Context**:
```
6yo, 22kg, needs amoxicillin for otitis media
```

**Good Response** ‚úÖ:
```
PEDIATRIC DOSING CALCULATOR

Patient: 22 kg (48.5 lbs) - 50th percentile for age

AMOXICILLIN for Acute Otitis Media:
Standard dose: 80-90 mg/kg/day √∑ BID
Calculated: 1,760-1,980 mg daily

RECOMMENDED PRESCRIPTION:
Amoxicillin 875mg PO BID x 10 days
(Total daily: 1,750mg = 79.5 mg/kg/day) ‚úì

Alternative if compliance concern:
Amoxicillin 900mg PO BID (closer to 90mg/kg)

SAFETY CHECKS PASSED:
‚úì Within pediatric dosing range
‚úì No drug interactions detected
‚úì No allergies on file
‚úì Appropriate for indication

Renal/Hepatic adjustment: Not needed (labs normal)
Reference: [AAP Guidelines 2024, Lexicomp Pediatric]
```

---

## 4. Scope & Boundaries

### 4.1 In Scope ‚úÖ
**Clinical Applications**:
- Differential diagnosis generation
- Clinical decision support at point of care
- Medication safety checking
- Lab/imaging interpretation assistance
- Clinical guideline recommendations
- Risk stratification and scoring
- Documentation assistance

**Specialties Covered**:
- Internal Medicine
- Family Medicine  
- Emergency Medicine
- Pediatrics (with specialized models)
- Hospital Medicine

### 4.2 Out of Scope ‚ùå
- Surgical procedures or OR guidance
- Psychiatry/Mental health diagnosis
- Direct patient interaction
- Autonomous treatment decisions
- Prognosis beyond validated models
- Medical advice without physician
- Remote/Telehealth consultations
- Clinical trials management

### 4.3 Gray Areas ‚ö†Ô∏è
| Scenario | Protocol | Escalation |
|----------|----------|------------|
| Conflicting guidelines | Show all, note discrepancy | Clinical committee |
| Off-label recommendations | Flag clearly, cite evidence | Attending approval |
| Rare diseases (<1:10,000) | Lower confidence threshold | Specialist consult |
| Pediatric edge cases | Conservative approach | Peds specialist |

---

## 5. Safety & Ethics Framework

### 5.1 Patient Safety Boundaries (Never Compromise)
| Risk Category | Detection Method | Response Protocol |
|---------------|-----------------|-------------------|
| Life-threatening miss | Severity scoring | Force physician review |
| Contraindicated treatment | Drug database | Block with override |
| Allergy violation | EMR integration | Hard stop |
| Pediatric overdose | Weight-based calc | Pharmacist verification |
| Black box warnings | FDA database | Attending required |

### 5.2 Clinical Ethics Framework
- **Autonomy**: Physician always has override capability
- **Beneficence**: Optimize for patient outcomes
- **Non-maleficence**: Conservative when uncertain
- **Justice**: No bias in recommendations
- **Veracity**: Transparent about limitations

### 5.3 Regulatory Compliance
| Requirement | Implementation | Validation |
|-------------|---------------|------------|
| FDA 510(k) | Class II Medical Device Software | Clinical trial |
| HIPAA | Zero PHI in training, encrypted | Annual audit |
| Clinical Validation | 10,000 case prospective study | IRB approved |
| Adverse Event Reporting | FDA MAUDE database | Within 30 days |
| Quality System Regulation | ISO 13485 certified | Annual review |

### 5.4 Bias Mitigation & Equity
- Regular audits for demographic disparities
- Diverse training data (40% underrepresented groups)
- Socioeconomic factors excluded from risk models
- Multiple language support (12 languages)
- Health equity dashboard for monitoring

---

## 6. Success Metrics & KPIs

### 6.1 North Star Metric
> **Diagnostic Error Rate: Reduce from 12% to 7.8% (35% reduction)**

### 6.2 Clinical Outcome Metrics
| Metric | Baseline | Target | Measurement | Validation |
|--------|----------|--------|-------------|------------|
| Diagnostic accuracy | 88% | 95% | Chart review | Blinded study |
| Time to diagnosis | 3.2 days | 1.8 days | EMR data | Retrospective |
| Unnecessary tests | 31% | 23% | Claims analysis | Cost tracking |
| Readmission rate | 18% | 14% | Quality metrics | Risk-adjusted |
| Critical value response | 92% | 99% | Lab system | Real-time |
| Physician satisfaction | 3.2/5 | 4.3/5 | Survey | Quarterly |

### 6.3 Safety Guardrails (Never Exceed)
| Metric | Maximum Acceptable | Current | Action if Exceeded |
|--------|-------------------|---------|-------------------|
| False negative rate | 0.1% | N/A | Immediate shutdown |
| Alert fatigue | 5 per session | N/A | Reduce sensitivity |
| Override rate | 30% | N/A | Model retraining |
| Safety events | 0 | 0 | Root cause analysis |

### 6.4 Operational Metrics
- EMR integration latency: <500ms
- Uptime: 99.99% (52 min downtime/year max)
- Physician adoption: 90% within 12 months
- Training completion: 100% before access

---

## 7. Clinical Validation & Implementation

### 7.1 Validation Phases

#### Phase 1: Retrospective Validation (Months 1-3)
- 50,000 historical cases
- Compare AI vs actual diagnosis
- Measure missed diagnoses
- IRB approval obtained

#### Phase 2: Shadow Mode (Months 4-6)
- Run parallel to clinical workflow
- No physician visibility
- Measure accuracy without influence
- 10,000 prospective cases

#### Phase 3: Pilot Program (Months 7-9)
- 50 volunteer physicians
- Non-critical cases only
- Full monitoring and feedback
- Daily safety reviews

#### Phase 4: Controlled Rollout (Months 10-12)
- Department by department
- Risk-stratified (low-risk first)
- Continuous monitoring
- FDA submission concurrent

### 7.2 Clinical Training Program
| Audience | Format | Duration | Competency Test |
|----------|--------|----------|-----------------|
| Attending physicians | Hands-on workshop | 4 hours | Case studies |
| Residents | Integrated curriculum | 8 hours | Simulation |
| Nurses | Awareness session | 1 hour | Quiz |
| IT/Support | Technical training | 2 days | Certification |

### 7.3 Change Management
- Physician champions in each department
- Weekly feedback sessions first 3 months
- 24/7 support hotline
- Continuous education on new features

---

## 8. Technical Architecture

### 8.1 System Integration
| System | Integration | Data Flow | Latency |
|--------|------------|-----------|---------|
| Epic EMR | FHIR API | Real-time | <200ms |
| PACS | DICOM | On-demand | <2s |
| Lab System | HL7 | Real-time | <100ms |
| Pharmacy | NCPDP | Real-time | <150ms |
| Clinical Guidelines | API | Daily sync | N/A |

### 8.2 Infrastructure Requirements
- Compute: On-premise GPU cluster (HIPAA)
- Storage: 500TB for model + audit trails
- Network: Dedicated 10Gbps clinical network
- Backup: Real-time replication, 2 sites
- Security: SOC 2 Type II, HITRUST certified

### 8.3 Data Governance
- No PHI leaves premises
- Federated learning for model updates
- Audit trail for every recommendation
- 7-year retention per regulations
- Patient consent for quality improvement

---

## 9. Risk Analysis & Mitigation

### 9.1 Clinical Risks
| Risk | Severity | Probability | Mitigation | Monitoring |
|------|----------|------------|------------|------------|
| Missed critical diagnosis | Catastrophic | Low | Conservative thresholds | Every case |
| Alert fatigue | Major | Medium | Smart filtering | Daily metrics |
| Over-reliance on AI | Major | Medium | Mandatory overrides | Usage patterns |
| Physician resistance | Moderate | High | Champions program | Adoption metrics |
| Regulatory action | Major | Low | Proactive FDA engagement | Continuous |

### 9.2 Technical Risks
| Risk | Impact | Mitigation |
|------|--------|------------|
| Model degradation | Accuracy drops | Monthly retraining |
| Integration failure | No recommendations | Graceful degradation |
| Cyber attack | System compromise | Zero-trust architecture |
| Data quality issues | Wrong recommendations | Validation layer |

---

## 10. Financial Analysis

### 10.1 Development Investment
| Category | Cost | Details |
|----------|------|---------|
| Clinical validation | $2.4M | IRB study, 10K patients |
| Engineering (12 FTE √ó 12 mo) | $2.1M | Full team |
| Regulatory (FDA 510k) | $800K | Consultants, submission |
| Infrastructure | $1.2M | On-premise HIPAA compliant |
| Training program | $400K | Materials, coverage |
| **Total Investment** | **$6.9M** | |

### 10.2 Operational Costs (Annual)
| Component | Cost | Calculation |
|-----------|------|-------------|
| Infrastructure | $480K | Compute, storage |
| Model updates | $200K | Continuous improvement |
| Clinical oversight | $350K | Medical director (0.5 FTE) |
| Support team | $420K | 3 FTE |
| **Total OpEx** | **$1.45M/year** | |

### 10.3 Value Creation
| Benefit | Annual Value | Calculation |
|---------|-------------|-------------|
| Reduced diagnostic errors | $8.4M | Malpractice reduction |
| Decreased testing | $3.2M | 25% reduction |
| Improved throughput | $2.1M | 15% efficiency gain |
| Reduced readmissions | $4.6M | 4% improvement |
| **Total Annual Benefit** | **$18.3M** | |
| **ROI** | **165%** | Year 2 onwards |
| **Payback Period** | **5.3 months** | After FDA clearance |

---

## 11. Regulatory Strategy

### 11.1 FDA Pathway
- Classification: Class II Medical Device Software
- Pathway: 510(k) Premarket Notification
- Predicate Device: IDx-DR (K173911)
- Timeline: 12-18 months total

### 11.2 Clinical Evidence Requirements
- Primary endpoint: Diagnostic accuracy >90%
- Secondary: Time to diagnosis, unnecessary testing
- Study size: 10,000 patients minimum
- Sites: 5 diverse geographic locations
- Demographics: Representative of US population

### 11.3 Post-Market Surveillance
- Real World Evidence collection
- Adverse event monitoring (FDA MAUDE)
- Annual clinical performance reports
- Version control and change management
- Continuous FDA communication

---

## 12. Success Criteria

### Go-Live Criteria
- [ ] FDA 510(k) clearance received
- [ ] Clinical validation >92% accuracy
- [ ] Zero safety events in pilot
- [ ] 80% physician satisfaction in pilot
- [ ] EMR integration <500ms latency
- [ ] Disaster recovery tested
- [ ] 100% staff trained

### 6-Month Success Metrics
- [ ] 50% physician adoption
- [ ] 20% reduction in diagnostic errors
- [ ] Zero attributed safety events
- [ ] 4.0+ physician satisfaction
- [ ] Positive ROI demonstrated

### Kill Criteria
- [ ] Any patient death attributed to system
- [ ] FDA warning letter or recall
- [ ] Diagnostic accuracy <85%
- [ ] Physician adoption <25% at 12 months
- [ ] Cyber security breach with PHI exposure

---

## Document Control

### Required Approvals
| Role | Name | Date | Signature |
|------|------|------|-----------|
| Chief Medical Officer | | | |
| Chief Information Security Officer | | | |
| General Counsel | | | |
| VP Quality & Patient Safety | | | |
| FDA Regulatory Lead | | | |
| Clinical Advisory Board Chair | | | |

### Document History
| Version | Date | Author | Changes |
|---------|------|--------|---------|
| 1.0.0 | Jan 27, 2025 | Dr. M. Thompson | Initial draft |

---

*This PRD is for a Class II Medical Device Software and will be included in FDA 510(k) submission*

*End of PRD v1.0*